Hepatitis D Market Report 2034 by DelveInsight: Epidemiology, Therapies, Latest Approvals by DelveInsight | Eiger Biopharmaceuticals, Janssen Biopharmaceuticals, MYR Pharmaceuticals, Hepa

Hepatitis D, also known as the "satellite virus," affects approximately 5% of individuals with hepatitis B. In 2023, the United States recorded the highest number of diagnosed prevalent cases of hepatitis D (HDV) among the 7MM, with males comprising a greater proportion of these cases compared to females. The U.S. also accounted for the largest market share of the hepatitis D virus within the 7MM in 2023.
DelveInsight's "Hepatitis D Market Insights, Epidemiology, and Market Forecast-2034 [https://www.delveinsight.com/report-store/hepatitis-d-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr] report offers an in-depth understanding of the Hepatitis D, historical and forecasted epidemiology as well as the Hepatitis D market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Hepatitis D market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Hepatitis D Market Forecast [https://www.delveinsight.com/sample-request/hepatitis-d-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Some of the key facts of the Hepatitis D Market Report:

*
On September 7, 2023, Eiger BioPharmaceuticals announced the termination of its Phase III LIMT-2 study of peginterferon lambda in patients with chronic hepatitis D. The decision followed a recommendation from the Data Safety Monitoring Board (DSMB) after its routine safety review.

*
Currently, treatment options for HDV are largely limited to interferon (IFN)-based therapies, with antiviral treatment using interferon alfa considered for chronic HDV infection. The treatment typically spans at least one year. Despite being identified more than 40 years ago, there are still no U.S. FDA-approved therapies specifically targeting the hepatitis D virus, leaving patients with few treatment alternatives.

*
The Hepatitis D market size is anticipated to grow with a significant CAGR during the study period (2020-2034).

*
Key Hepatitis D Companies: Eiger Biopharmaceuticals, Janssen Biopharmaceuticals, MYR Pharmaceuticals, Hepatera, and others

*
Key Hepatitis D Therapies: HEPCLUDEX (bulevirtide), Lonafarnib; Peginterferon Lambda-1a, JNJ-3989, and others

*
The Hepatitis D market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Hepatitis D pipeline products will significantly revolutionize the Hepatitis D market dynamics.

Hepatitis D Overview

Hepatitis D, also referred to as delta hepatitis, is a liver infection instigated by the Hepatitis D virus (HDV). It's categorized as a satellite virus because it necessitates the presence of the Hepatitis B virus (HBV) to replicate and induce infection. HDV infects individuals either concurrently with HBV (co-infection) or subsequent to HBV infection (superinfection).

HDV is the root cause of Hepatitis D, a condition that solely affects individuals already harboring HBV. Transmission of HDV occurs through contact with infected blood or bodily fluids, mirroring the transmission routes of HBV. Common risk factors for acquiring Hepatitis D include injection drug use, exposure to infected blood.

Hepatitis D Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

In 2023, the United States had the largest share of diagnosed prevalent cases of Hepatitis D virus (HDV) across the 7MM, much like how one city might be the most populous in a country. When breaking it down by gender, more men were diagnosed with HDV than women, similar to how one might see a higher number of men in certain professions or industries.

Looking at age groups, the 18-34 age range had the highest number of cases, which could be compared to how a certain generation might dominate a particular trend or cultural shift-this age group stood out in the HDV diagnosis landscape.

In Europe, Germany led the EU4 and the UK with the highest number of diagnosed prevalent cases, much like how a particular region in a country might have a higher concentration of a certain disease or condition. This shows that the distribution of HDV can vary significantly across regions, much like how certain weather patterns or economic conditions might be more common in one area than others.

Hepatitis D Epidemiology Segmentation:

The Hepatitis D market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

*
Total Prevalence of Hepatitis D

*
Prevalent Cases of Hepatitis D by severity

*
Gender-specific Prevalence of Hepatitis D

*
Diagnosed Cases of Episodic and Chronic Hepatitis D

Download the report to understand which factors are driving Hepatitis D epidemiology trends @ Hepatitis D Epidemiology Forecast [https://www.delveinsight.com/report-store/hepatitis-d-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Hepatitis D Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hepatitis D market or expected to get launched during the study period. The analysis covers Hepatitis D market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Hepatitis D Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Hepatitis D Key Companies

*
Lonafarnib: Eiger Biopharmaceuticals

*
JNJ 73763989: Arrowhead Pharmaceuticals

*
HEPCLUDEX (bulevirtide): Gilead Sciences

*
JNJ-73763989/JNJ-3989: Janssen Research & Development, LLC

Discover more about therapies set to grab major Hepatitis D market share @ Hepatitis D Treatment Landscape [https://www.delveinsight.com/sample-request/hepatitis-d-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Scope of the Hepatitis D Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Hepatitis D Companies: Eiger Biopharmaceuticals, Janssen Biopharmaceuticals, MYR Pharmaceuticals, Hepatera, and others

*
Key Hepatitis D Therapies: HEPCLUDEX (bulevirtide), Lonafarnib; Peginterferon Lambda-1a, JNJ-3989, and others

*
Hepatitis D Therapeutic Assessment: Hepatitis D current marketed and Hepatitis D emerging therapies

*
Hepatitis D Market Dynamics: Hepatitis D market drivers and Hepatitis D market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Hepatitis D Unmet Needs, KOL's views, Analyst's views, Hepatitis D Market Access and Reimbursement

To know more about Hepatitis D companies working in the treatment market, visit @ Hepatitis D Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/report-store/hepatitis-d-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Table of Contents

1. Hepatitis D Market Report Introduction

2. Executive Summary for Hepatitis D

3. SWOT analysis of Hepatitis D

4. Hepatitis D Patient Share (%) Overview at a Glance

5. Hepatitis D Market Overview at a Glance

6. Hepatitis D Disease Background and Overview

7. Hepatitis D Epidemiology and Patient Population

8. Country-Specific Patient Population of Hepatitis D

9. Hepatitis D Current Treatment and Medical Practices

10. Hepatitis D Unmet Needs

11. Hepatitis D Emerging Therapies

12. Hepatitis D Market Outlook

13. Country-Wise Hepatitis D Market Analysis (2020-2034)

14. Hepatitis D Market Access and Reimbursement of Therapies

15. Hepatitis D Market Drivers

16. Hepatitis D Market Barriers

17. Hepatitis D Appendix

18. Hepatitis D Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=hepatitis-d-market-report-2034-by-delveinsight-epidemiology-therapies-latest-approvals-by-delveinsight-eiger-biopharmaceuticals-janssen-biopharmaceuticals-myr-pharmaceuticals-hepa]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.